The stock of Corium International Inc (NASDAQ:CORI) is a huge mover today! About 113,922 shares traded hands or 218.24% up from the average. Corium International Inc (NASDAQ:CORI) has risen 28.00% since April 27, 2016 and is uptrending. It has outperformed by 22.77% the S&P500.
The move comes after 7 months negative chart setup for the $113.29M company. It was reported on Nov, 30 by Barchart.com. We have $4.65 PT which if reached, will make NASDAQ:CORI worth $9.06 million less.
Analysts await Corium International Inc (NASDAQ:CORI) to report earnings on February, 13. They expect $-0.31 EPS, up 26.19% or $0.11 from last year’s $-0.42 per share. After $-0.42 actual EPS reported by Corium International Inc for the previous quarter, Wall Street now forecasts -26.19% EPS growth.
Corium International Inc (NASDAQ:CORI) Ratings Coverage
Out of 5 analysts covering Corium International (NASDAQ:CORI), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Corium International has been the topic of 9 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The stock of Corium International Inc (NASDAQ:CORI) has “Buy” rating given on Wednesday, September 2 by Zacks. The stock of Corium International Inc (NASDAQ:CORI) has “Buy” rating given on Monday, November 16 by Needham. The firm has “Buy” rating given on Tuesday, August 25 by Zacks. As per Monday, August 31, the company rating was downgraded by WBB Securities. The stock has “Buy” rating given by Needham on Tuesday, February 9.
According to Zacks Investment Research, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California.”
Insitutional Activity: The institutional sentiment decreased to 0.69 in Q2 2016. Its down 0.04, from 0.73 in 2016Q1. The ratio dived, as 12 funds sold all Corium International Inc shares owned while 14 reduced positions. 8 funds bought stakes while 11 increased positions. They now own 18.39 million shares or 2.90% less from 18.94 million shares in 2016Q1.
Rtw Lc holds 1.01% or 852,961 shares in its portfolio. Wells Fargo & Mn last reported 0% of its portfolio in the stock. Deutsche State Bank Ag last reported 12,201 shares in the company. Northern Corporation last reported 0% of its portfolio in the stock. The Pennsylvania-based Tfs Limited Co has invested 0.02% in Corium International Inc (NASDAQ:CORI). Blackrock Management Limited Liability reported 2,270 shares or 0% of all its holdings. Franklin accumulated 0% or 871,590 shares. Parallax Volatility Advisers Ltd Partnership owns 1,783 shares or 0% of their US portfolio. Moreover, Blackrock Institutional Co Na has 0% invested in Corium International Inc (NASDAQ:CORI) for 66,313 shares. Citigroup Inc last reported 0% of its portfolio in the stock. Goldman Sachs Group last reported 0% of its portfolio in the stock. Vanguard holds 0% or 350,274 shares in its portfolio. Victory Capital Management has invested 0% of its portfolio in Corium International Inc (NASDAQ:CORI). The New York-based Morgan Stanley has invested 0% in Corium International Inc (NASDAQ:CORI). Geode Cap Mngmt Ltd Limited Liability Company last reported 65,455 shares in the company.
Another recent and important Corium International Inc (NASDAQ:CORI) news was published by Quotes.Wsj.com which published an article titled: “News Corium International Inc.CORI” on April 16, 2011.
CORI Company Profile
Corium International, Inc., incorporated on February 28, 2002, is a biopharmaceutical company. The Firm is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. The Company’s development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules that are difficult to deliver in a transdermal dosage form. The Company’s Corplex and MicroCor platforms address some of the primary shortcomings of traditional transdermal drug delivery.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.